Play all audios:
ABSTRACT Chagas disease following infection with _Trypanosoma cruzi_ is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the
migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key
challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess
drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a
serological multiplex method (MultiCruzi), combined with advanced statistical analytical methods, to measure the response to anti-parasitic treatment of adult Chagas patients. Applying this
approach to serum samples from adult patients in the indeterminate chronic stage of Chagas disease, treated with different benznidazole regimens and combinations, we predict treatment
efficacy after just 6 months of follow-up, in sharp contrast to data obtained with conventional and recombinant _T. cruzi_ ELISA tests. The obtained results are also compared with the PCR
data. We propose integrating MultiCruzi as a serological method endpoint in proof-of-concept clinical trials for Chagas disease. SIMILAR CONTENT BEING VIEWED BY OTHERS HUMAN CHAGAS-FLOW
ATE-IGG1 FOR ADVANCED UNIVERSAL AND _TRYPANOSOMA CRUZI_ DISCRETE TYPING UNITS-SPECIFIC SERODIAGNOSIS OF CHAGAS DISEASE Article Open access 06 August 2020 VALIDATION OF A MULTIPLEXED
IMMUNOASSAY FOR IMMUNOLOGICAL ANALYSIS OF PRE ERYTHROCYTIC MALARIA VACCINES Article Open access 20 January 2025 EARLY AND LONG TERM ANTIBODY KINETICS OF ASYMPTOMATIC AND MILD DISEASE
COVID-19 PATIENTS Article Open access 02 July 2021 INTRODUCTION Chagas disease, or American trypanosomiasis, is a chronic, life-threatening disease caused by the protozoan parasite
_Trypanosoma cruzi_ (_T. cruzi_) and is considered a neglected tropical disease by the World Health Organization (WHO)1,2. Endemic in 21 Latin American countries, it has spread globally due
to migration, affecting an estimated 6 to 7 million people worldwide2,3,4. The disease has acute and chronic phases. The acute phase usually presents mild symptoms or is asymptomatic, with
the parasite replicating, and circulating in the bloodstream. This phase transitions into the chronic indeterminate form, where the parasite becomes hardly detectable and tightly controlled
by the immune system. Around 30% of individuals develop severe complications, such as cardiomyopathy and digestive disorders, which can lead to sudden death5,6,7. Current treatments are
limited to nifurtimox (NF) and benznidazole (BZN)8, which have high toxicity and severe side effects, especially in adults9,10,11,12. To circumvent these tolerability issues, alternative
drug regimens and combinations are under investigation, including fosravuconazole (E1224) alone or in combination with benznidazole13,14. One major challenge in drug development for Chagas
disease is the lack of reliable markers to assess parasitological cure in a timely manner15,16,17. Polymerase chain reaction (PCR), often used in Phase II trials, has variable sensitivity
and specificity due to the low and cyclic parasitemia during the indeterminate form of chronic Chagas disease18,19. The United States Food and Drug Administration (FDA) recommends
serological testing for blood donors and the use of two different serological tests in paediatric trials to determine effectiveness of a new trypanocide therapy20,21. Seroreversion, the
disappearance of antibodies/Immunoglobulins G against _T. cruzi_, is the only marker of parasitological cure accepted by health authorities as waning antibodies is associated with parasite
clearance8,22,23,24, and this endpoint was used to register both benznidazole and nifurtimox for the treatment of children25,26. However, it takes decades in adults for antibodies to fully
disappear from the blood stream27,28,29, making current serological tests not feasible for establishing parasite clearance and not adequate for drug development. Great progress has been made
in epitope and serological biomarkers research30. Moreover, high-performance serology tests were developed with overall high sensitivity and specificity, though field performance varies29.
Therefore, the WHO recommends using two serological tests to diagnose chronic infection8, which can lead to underdiagnosis due to discordant results27. There is an urgent need for serology
tests and other markers or combinations thereof that can be used to assess drug efficacy in a timely manner. This would allow for appropriate development timelines of new drugs, the
follow-up and interpretation of clinical trial data, and the improved care / counselling of patients through the assessment of cure soon after therapy22. The MultiCruzi assay, a multiplex
antibody serology test, has proven effective in confirming Chagas disease and predicting parasitological cure earlier than conventional tests in infants and children with acute or early
chronic Chagas disease31,32,33. This study aims to apply the MultiCruzi method to adults with chronic Chagas disease, using serial dilutions and advanced statistical analytical methods to
identify response to treatment early during follow-up13. RESULTS SAMPLES TESTED Samples from the phase II double-blind randomized BENDITA trial were assessed in this study13. Patients with
sera samples at the three timepoints: baseline (before treatment), 6 months, and 12 months post-treatment, were included in this analysis and assayed using MultiCruzi. Following curation of
the database, eight patients were excluded in the analysis as they either discontinued the study early or withdrew their consent; samples from 201 patients were included corresponding to 6
treatment arms and placebo: (1) 150 mg of Benznidazole daily for 4 weeks, (2) 300 mg of Benznidazole daily for 2 weeks, (3) 300 mg of Benznidazole daily for 4 weeks, (4) 300 mg of
Benznidazole daily for 8 weeks, (5) 150 mg of Benznidazole daily for 4 weeks plus fosravuconazole, (6) 150 mg of Benznidazole daily for 8 weeks plus fosravuconazole and (7) Placebo. See
Supplementary Fig. 1 for more details. DILUTION METHOD WITH MULTICRUZI ALLOWS ANTIBODY QUANTIFICATION The MultiCruzi assay was initially developed to confirm infection by measuring the _T.
cruzi_ antibody levels in serum samples. It is a multiplex composed of fifteen _T. cruzi_ antigens printed onto 96-well plates, that generates an overall signature of all the antigens
detected32,33. The assay was originally optimized to yield robust signals with sera from infected subjects, while producing negligible or no background signals with sera from uninfected
subjects. This design inherently limits the ability to detect the waning or declining of antibodies over time due to signal saturation with seropositive samples. To effectively monitor and
quantify a decrease in antibody titers, and ultimately seroreversion, in patients’ samples over time, we employed a previously established dilution method. This method ensures that at least
one antibody measurement falls within the quantifiable range34. The relationship between the colorimetric intensity for each biomarker and the dilution factor is characteristically
sigmoidal, displaying plateaus at both low and high signal intensities. Quantification is most reliable within the linear portion of these curves. At the extremes of the signal spectrum,
both at low and high ranges, minor shifts in signal intensity are unfit for accurately estimating changes in antibody levels. This imprecision is largely due to the possibility that small
fluctuations may stem from measurement noise rather than genuine changes in antibody concentrations. The dilution factors were carefully selected to ensure overlap in the linear ranges for
all antigens, to enable quantification at maximum concentrations and to minimize the number of dilutions necessary. This process was previously described in more detail34. Dilutions of 1/50,
1/400, and 1/3200 were found to be optimal for all fifteen antibodies assessed with the MultiCruzi assay. Following sample dilution (Fig. 1a), antibody reactivities were converted into an
arbitrary dilution factor (DF), a surrogate for the antibody concentration. A DF50 score corresponds to the dilution at which a signal intensity value of 50% of the maximal signal would be
observed. This value summarizes the 3 dilution sequence antibody intensities (Supplementary Note 1). Although the unit of DF50 is arbitrary, its relationship with concentration is linear.
The scores were calculated for each timepoint (Baseline, 6 months, and 12 months of follow-up post-treatment). The assumption is that a treatment effect will lead to a shift in the sigmoidal
dose-response curve of the dilution series to lower dilution factors. Figure 1 shows an example for Antigen 3 reactivity in patients treated with either (b) placebo or (c) benznidazole
(BZN). This means that the DF50-value decreases over time when antibodies start waning (Supplementary Fig. 2a,b). Another example shows the effect of treatment on the reactivity of antigen
10 using the dilution method (Supplementary Fig. 3a, b). This DF50 factor was then used in the analysis to study the variability or decrease in each of the treatment groups (Supplementary
Note 2) using a linear mixed model (LMM) (Supplementary Note 3). IDENTIFYING ANTIBODY DECLINE OVER TIME USING A RANDOM INTERCEPT LINEAR MIXED MODEL Following dilution of the clinical
samples, a random intercepts linear mixed model analysis was performed for each individual antigen present on MultiCruzi to determine the antibodies’ reactivity over time for each treatment
regimen. We then plotted the linear predictor versus time for the seven treatment arms obtained (See Supplementary Fig. 4 for Antigen 11 as an example). Taking Antigen 11 as an example, the
slopes of most treatment arms for this specific antigen (except for 300 mg BZN for 4 weeks, 300 mg BZN + E1224 for 8 weeks, and placebo) are significantly different from zero (_p_ < 0.05)
(Supplementary Table 1). All slopes are negative, indicating that the sigmoidal curve shifts to lower dilution factors (DF50) over time, representative of a decline in antibody titer over
time compared to baseline. In this case, the decline rate or slope is significantly lower than zero (_p_ ≤ 0.05) for Antigen 11 after treatment with 150 mg BZN for 4 weeks (−0.1617, _p_ =
0.0045), 300 mg BZN for 2 weeks (−0.2584, _p_ < 0.0001), 300 mg BZN for 8 weeks (−0.1678, _p_ = 0.0044), and 150 mg BZN + E1224 for 4 weeks (−0.1971, _p_ = 0.0010). On the other hand, the
slope in the placebo group is only slightly negative (−0.00518) meaning that there is also a slight decrease in antibody against Antigen 11 over time, although this is not significantly
different from zero (_p_ = 0.9271) (Supplementary Note 3). The slopes of all treatment groups were then compared to the slope of the placebo group (arm 7). Arms 2 (BZN—300 mg for 2 Weeks)
(_p_ = 0.0018), 4 (BZN—300 mg for 8 Weeks) (_p_ = 0.0464) and 5 (BZN—150 mg + E1224 for 4 Weeks) (_p_ = 0.0200) showed significant differences in their decline rate (_p_ < 0.05) as
compared to the placebo (Supplementary Table 2). RANDOM INTERCEPT LINEAR MIXED MODELS (LMM) WITH NESTED ANTIGENS The variability (the decrease, in this study) in log2(DF50) in each of the 7
treatment arms was studied with a nested LMM, using time, treatment and the interaction of time with treatment as covariables, considering about 30 patients in each treatment group, 3
timepoints (D0, 6 M, 12 M) per patient, and 15 antigens for each patient and timepoint. The advantage of a nested model is that it keeps the connection between the patient and the antigens,
and allows one analysis for the combined antigens, thus increasing the sample size and consequently the power to detect possible treatment effects. The linear predictor (log2DF50) versus
time, for the 7 treatments arms, was obtained at 6 months (Fig. 2a) and 12 months (Fig. 2b) following the start of treatment. At 6 months of follow-up, the slopes of all treatment groups,
except for placebo, were significantly different from 0 with a _p_ < 0.0001 (Fig. 2a and Supplementary Table 3) and the slopes of all the treatment groups were significantly different
from the slope of the placebo group, with p ranging between <0.0001 and 0.0007. At 12 months post follow-up, the slopes of all treatment groups were clearly negative and significantly
different from zero (_p_ < 0.0001), including the slope for the placebo group (−0.02766, _p_ = 0.0221) (Fig. 2b and Supplementary Table 4). Slopes of all the treatment groups were
significantly more negative than the slope of the placebo group (_p_ < 0.0001), indicating that the antibodies decline more rapidly in treated patients than in patients administered the
placebo. Slopes of all treatment groups were then compared to the slope of the placebo group (arm 7) at 6 and 12 months after start of treatment. At both timepoints, all treatment regimens
showed significant differences expressing significant decline rates (_p_ < 0.05) as compared with the placebo (Supplementary Table 5a and Supplementary Table 5b). In addition,
non-overlapping 95% Confidence Intervals (CI) of the treatment slopes with the Placebo’s slope at 6 (Supplementary Fig. 5a) and 12 months after treatment (Supplementary Fig. 5b) confirm that
all treatment groups have slopes significantly different from those of the Placebo group. However, treatment groups do not have slopes different from each other. INTERPRETATION ALGORITHMS
AND OPTIMAL THRESHOLD FOR THE SLOPE To identify a response to treatment, an individual should show a decline in antibodies (slope < 0) but preferably faster than in the placebo group.
Therefore, a specific threshold can be defined by conducting a receiver operating characteristic (ROC) analysis comparing the slopes of the treatment groups versus the slopes in the placebo
group. For each of the 15 antigens (AG), a ROC analysis on the DF50 slopes was performed using the treated versus placebo arms to obtain the best threshold for the slope, in terms of
sensitivity (S) and specificity (Sp), based on the optimal Youden index S + Sp – 1 (Supplementary Note 4, Supplementary Table 6). Alternatively, the slopes of the antigens can be considered
collectively. We propose setting an overall threshold for all antigen slopes, requiring that 50% of the antigens reactive at baseline meet this threshold. We adhered to this 50% requirement,
but this algorithm can be adjusted to be more lenient or stringent based on the percentage of initially reactive antigens that must decrease by a predefined amount or percentage change and
the threshold for this change. To determine the optimal threshold for distinguishing between treatment and placebo patients, we performed a ROC analysis comparing the slope of the placebo
group to the slopes of the combined six treatment regimens (Fig. 3). The analysis yielded an area under the curve (AUC) of 0.737 and identified a cut-off of −0.025, corresponding to the
optimal Youden index (maximum of sensitivity + specificity − 1). Moreover, as the cut-off slope is −0.025 over the 12 month period, then: $${\log
}_{2}\frac{{{{\rm{DF}}}50}_{t}}{{{{\rm{DF}}}50}_{{{\rm{baseline}}}}}={{\rm{slope}}}\times t=-0.025\times 12=-0.30$$ (1) Thus, a change of −0.3 between baseline and 12 month of log2DF50 could
be used to define the response to treatment for each originally reactive antigen.Therefore, in order to make a clinical decision for each patient, the number of reactive antigens (_N_) at
baseline was calculated, then, the DF50 value of each of the 15 antigens was calculated, at each timepoint: baseline, 6 months and 12 months. The evolution of antibody load at each of the
follow-up timepoints was then compared to the baseline by calculating the \({\log }_{2}\frac{{{{\rm{DF}}}50}_{t}}{{{{\rm{DF}}}50}_{{{\rm{baseline}}}}}\) (_t_ is equal to 6 or 12 months)
value. The number of antigens (_N__t_) having a change superior to −0.3 at 12 months was calculated and compared to _N_. Then the following set of rules were proposed as individual
interpretation algorithm for the 12 months follow-up: * If \(\frac{{N}_{t}}{N}\) is equal or higher than 0.5, the result is “Response to Treatment”. The patient shows a response to the
anti-parasitic treatment. * If \(\frac{{N}_{t}}{N}\) is equal to 0.3 or between 0.3 and 0.5, the result is “Inconclusive”. The patient should be rechecked at a further timepoint to give a
definitive result. * If \(\frac{{N}_{t}}{N}\) is <0.3, the result is “No Response to Treatment”. The patient did not respond to the treatment according to the test. Using this analysis,
the percentage of patients with “Response to Treatment” (Table 1), “Inconclusive” and “No Response to Treatment” were calculated in each treatment regimen (Fig. 4). The number of patients
per treatment arm does not allow the comparison between treatments. After 12 months of follow-up, 150/171 (87.21%) patients treated with benznidazole ± E1224 were identified to respond to
treatment by MultiCruzi as compared to 10/30 (33.33%) patients in the placebo group (_p_ < 0.0001). The same analysis was performed with the different thresholds for log2DF50 change
between baseline and 12 month (Supplementary Table 7). The fixed threshold has an impact on the outcome, notably the proportion of patients with ‘response to treatment’. However, the
difference between the treatment groups and the placebo group remains large across all cut-offs (Fig. 5). Moreover, considering these proportions, using a threshold for the slope of −0.3
(Supplementary Fig. 6a) and of −0.7 (Supplementary Fig. 6b), non-overlapping 95% CIs of the treatment slopes with the Placebo’s slope at 12 months after treatment indicate that all treatment
groups have slopes significantly different from the slope of the Placebo group. However, treatment groups do not have slopes different from each other. RESULTS WITH CONVENTIONAL AND
RECOMBINANT ELISA The trend of anti-_T. cruzi_ antibodies was measured at two timepoints (baseline and 12 months after start of treatment) using enzyme-linked immunosorbent assays (ELISA)
serology tests. For both conventional and recombinant ELISAs, the optical densities remain above the threshold defined according to the manufacturer’s instructions, with no significant
decrease in the mean reactivity of samples 12 months later in all treatment groups, including placebo, with conventional ELISA (Supplementary Fig. 7). With the recombinant ELISA, there was
an insignificant decrease of the anti-_T. cruzi_ antibody levels 12 months after the start of treatment in all but two groups: patients treated with either placebo or 300 mg BZN + 300 mg
E1224 (Supplementary Fig. 8). As previously described for children, a threshold for declaring patients to be cured was set to at least 20% reduction in mean optical density measured in the
two conventional ELISA tests at 12 months compared with baseline27. The results obtained with MultiCruzi at a threshold of −0.3 were then compared to those obtained with conventional and
recombinant commercial ELISA tests after applying the threshold of at least 20% reduction in mean optical density. At 12 months compared to baseline, MultiCruzi shows the highest percentage
of “Response to Treatment” in treated patients as compared to the placebo group with the lowest number of patients responding to their assigned treatment (Fig. 6, Supplementary Table 8). The
nested linear mixed model shows the average decline in antibodies with time per treatment group, keeping the connection between the patient and the antigens. The model shows a significantly
faster decline in antibodies in the treatment groups compared to the placebo group. Similarly, a linear mixed model for the conventional ELISAs was calculated. No significant difference in
slopes between the treated groups and the placebo group was found. In summary, the nested LMM with MultiCruzi data shows significant differences in slopes between treatment and placebo
groups after just 6 months, and this is confirmed and sustained after 12 months in sharp contrast to traditional ELISA tests that do not show any such significant decrease. COMPARISON OF THE
MULTICRUZI RESULTS WITH THE PCR DATA Despite the difference in the outcomes measured by MultiCruzi and PCR (MultiCruzi measures a decline in antibodies as a sign of treatment response while
PCR determines treatment failure by measuring the presence of _T. cruzi_ DNA in the blood), we made an attempt to assess the concordance between both methods across the different thresholds
for $${\log }_{2}\frac{{{{\rm{DF}}}50}_{12{{\rm{months}}}}}{{{{\rm{DF}}}50}_{{{\rm{baseline}}}}}$$ (2) In this context, the “Response to Treatment Agreement” was defined as the number of
patients with “Response to Treatment” obtained from the algorithm at the mentioned threshold as well as “Parasitological Clearance” according to PCR across all treatment groups and placebo,
divided by the number of patients with PCR indicating “Parasitological Clearance” (PCR < 0; _n_ = 144): $$ {\hbox{``}}{{\rm{Response}}}\; {{\rm{to}}}\; {{\rm{Treatment}}}\;
{{\rm{Agreement}}}{\hbox{''}} \\ =\frac{{{\rm{Number}}}\; {{\rm{of}}}\; {{\rm{patients}}}\; {{\rm{with}}\,}{\hbox{``}}{{\rm{Response}}}\; {{\rm{to }}}
{{\rm{Treatment}}}\,{\hbox{''}}\,{{\&}}\,{\hbox{``}}{{\rm{Parasitological}}}\; {{\rm{Clearance}}}{\hbox{''}}}{{{\rm{Number}}}\; {{\rm{of}}}\; {{\rm{patients}}}\;
{{\rm{with}}\,}{\hbox{``}}{{\rm{Parasitological}}}\; {{\rm{Clearance}}}{\hbox{''}}}$$ (3) The “No Response to Treatment Agreement” was defined as the number of patients with “No
Response to treatment” by MultiCruzi at the defined threshold as well as “No Parasitological Clearance” by PCR, divided by the number of patients with PCR indicating “No Parasitological
Clearance” (PCR > 0; _n_ = 57): $$ {\hbox{``}}{{\rm{No}}}\; {{\rm{Response}}}\; {{\rm{to}}}\; {{\rm{Treatment}}}\; {{\rm{Agreement}}}{\hbox{''}}\\ =\frac{{{\rm{Number}}}\;
{{\rm{of}}}\; {{\rm{patients}}}\; {{\rm{with}}}\,{\hbox{``}}{{\rm{No}}}\; {{\rm{Response}}}\; {{\rm{to}}}\; {{\rm{Treatment}}}{\hbox{''}}\,{{\&}\,}{\hbox{``}}{{\rm{No}}}\;
{{\rm{Parasitological}}}\; {{\rm{Clearance}}}{\hbox{''}}}{{{\rm{Number}}}\; {{\rm{of}}}\; {{\rm{patients}}}\; {{\rm{with}}}\,{\hbox{``}}{{\rm{No}}}\; {{\rm{Parasitological}}}\;
{{\rm{Clearance}}}{\hbox{''}}}$$ (4) (Supplementary Table 9a). Looking more specifically at the placebo group, the “No Response to Treatment Agreement” was defined as the number of
patients with “No Response to Treatment” observed by multiplex and a PCR indicating “No Parasitological Clearance”, divided by the total number of patients with PCR indicating “No
parasitological Clearance” (PCR > 0; _n_ = 29) (Supplementary Table 9b). At a slope threshold of −0.7, the agreement between both methods reaches 82.8%. At 12 months compared to baseline,
MultiCruzi shows a lower percentage of “Response to Treatment” in treated patients compared to PCR (Fig. 7a, Table 2, Supplementary Table 10). Meanwhile, the placebo group shows the lowest
number of patients responding to their assigned treatment, albeit a higher number is detected to respond to cure (_n_ = 3) than PCR (_n_ = 1) (Fig. 7b). DISCUSSION The objective of this
study was to quantify the degree of seroreduction, and thus predict future seroreversion, as a surrogate marker of parasitological cure for adult patients with chronic Chagas disease. We
report the use of a multiplex test (MultiCruzi) and the use of antigen reactivities at specific timepoints for predicting seroreversion. We examined serological changes in 15 different _T.
cruzi_ antigens during the follow-up period of patients who had received one of 7 different treatment regimens. We were able to demonstrate that predictions based on the experimental
MultiCruzi results within 6–12 months of follow-up were sufficient to forecast future seroreversion, assuming that the decline in antibodies’ titers are predictive of future full
seroreversion11. We have previously shown that seroreversion can be assessed more rapidly by MultiCruzi than by standard serology in samples from children treated with benznidazole31. While
this was possible without using a dilution approach in a paediatric population where patients seroconvert faster and seroreversion can be observed within years following treatment, in
adults, seroreversion takes decades27,28,29, making it impossible to determine waning of antibodies in a reasonable timeframe using the conventional serological tests and methods. We
demonstrate that this issue can be addressed by carefully monitoring the dynamic of selected specific antibodies in a multiplexed serology immunoassay in serially diluted samples and
applying statistical methods. Using this method, it becomes feasible to show, in benznidazole treated adult Chagas patients, a decline in antibody signature / antibodies’ titers as early as
6 months post-treatment that can be associated with a future seroreversion therefore much earlier than using conventional serology where seroreversion takes decades. We observe an
inconsistency of the outcomes obtained with the two commercial ELISA techniques used in this study. This is a core issue in the evaluation of treatment effectiveness for Chagas disease. In
fact, ELISA tests vary from one assay to another, depending on antigen compositions, giving results that do not match, making it difficult to draw conclusions about treatment effectiveness.
Moreover, due to the low number of patients per treatment group, between-group analysis was not performed, as the power of the test would have been insufficient. While we showed a
significantly more pronounced decrease in the antibody levels in each treatment group compared to the placebo group, we wanted to further analyze the data at individual patient level. The
challenge in reaching this objective is related to the small number of patients per group, especially in the placebo group and the absence of a consensus related to the setting of a
threshold for serology tests. Using the MultiCruzi, we showed that across the different thresholds for the log2DF50 reduction between baseline and 12 months assessed, the level of patients
responsive to treatment in the Placebo group is always lower than in the treatment groups. However, when fixing this threshold for log2DF50 decrease between baseline and 12 months at −0.3,
which corresponds to the maximum Youden index on the ROC curve, one third of the patients treated with placebo were predicted to be responsive to the treatment. It is now well recognized
that patients with initial infection can show complete spontaneous seroreversion35,36, reaching in some cases up to 30% of seropositive people as described in a study of 1423 blood donors
from the Chaco region of Argentina (this study showed that about 30% of participants had low antibody level responses with different commercial immunoassays and this was correlated with the
spontaneous clearance of _T. cruzi_ infection37). Additional data with larger groups of placebo-treated patients will allow to define the appropriate threshold. Indeed, the application of
this method at individual patient level requires the definition of thresholds; the current ones are based on a small number of patients (only 30 placebo treated patients in our study) or on
the literature (e.g., for ELISAs), which may result in inaccurate estimations of sensitivity and specificity. We then attempted to compare the results obtained with MultiCruzi with the PCR
data from the original clinical study. In this case, we observe that the agreement between both methods also depends on the fixed threshold for log2DF50 decrease. When this threshold is
fixed at −0.7, the correspondence is optimal between MultiCruzi and PCR with a “Response to Treatment Agreement” of 51.4% and a “No Response to Treatment Agreement” of 57.9% in the entire
population. Our findings are in line with a recent analysis of qPCR data, which shows that Ct values remain stable over time in most placebo-treated patients, unlike those receiving other
treatments in the BENDITA trial. Furthermore, all treatment groups differ significantly from the placebo group, as demonstrated by the non-overlapping 95% Confidence Intervals for the
estimated probability of cure in the Ct-based model for each treatment regimen compared to the placebo38. Looking more specifically into the ratio of patients with the different outcomes in
each group, PCR data show sustained parasitological clearance in more patients than MultiCruzi. This could be explained by the limitations of the PCR method as the level of parasites in the
bloodstream does not reflect the level of parasites in the tissues; the very low and sporadic parasitemia during the chronic phase of the disease makes direct detection of the parasite
intrinsically difficult39. In fact, only around 30–70% of individuals with chronic Chagas disease show a positive blood PCR test result before treatment40,41. Moreover, a series of negative
PCR results does not necessarily prove the absence of the parasite. Some longer follow-up studies for example have shown positive PCR in patients after 4 or 5 years of follow-up while during
the first years a sustained negative PCR was observed42. In addition, variability in PCR outcomes with the current standard benznidazole treatment (300 mg of BZN for 8 weeks) is evident
when comparing similar clinical trials. In fact, using the same qPCR method43 to measure sustained parasite clearance from the blood over 1 year, 83% of patients in the BENDITA trial13
showed sustained clearance, whereas only 54% of patients in the MULTIBENZ trial40 achieved the same result. On another note, the higher number of patients responding to treatment with
MultiCruzi compared to the PCR method in the placebo group could be due to several reasons related to both techniques. It may be a consequence of the fixed threshold for the dilution method
as previously discussed on one hand and the arbitrary and variable Cycle thresholds (Ct) among triplicates of the quantifiable positive PCR samples on the other hand. False positive or
variation in the Limit of Quantification (LOQ) and/or the Limit of Detection (LOD) cannot be ruled out either. In fact, the performance of the PCR method shows higher variability of
measurements at low parasite loads close to the LOD43 knowing that 99.45% of PCR positive samples included in this analysis are below the LOQ. Moreover, as these patients are present in an
endemic area throughout the study, the presence of the _Trypanosoma rangeli_ which can be found in the same vectors and vertebrate hosts cannot be eliminated44,45. While studies have shown
that human infection with this nonpathogenic protozoan does not affect the serodiagnosis of Chagas disease44,46, it was shown to induce false positive PCR signals when present at certain
levels in the serum sample43. The presence of DNA from dead _T. cruzi_ parasites cannot be ruled out either. In summary, both methods are measuring different outcomes: the MultiCruzi is
measuring antibodies decline as a surrogate of future seroreversion/treatment efficacy (seroreversion is accepted by the regulatory authorities8,20,21); PCR is looking at treatment failure
measuring the presence of _T. cruzi_ DNA in blood (sustained PCR negativity during 1 year following treatment) and is not accepted by the health authorities as a valid endpoint. We therefore
believe that our results open new avenues for performing clinical trials with novel drugs and therapies, as the MultiCruzi test assesses the therapeutic response—a previously unmet medical
need of adult patients with Chagas disease47,48. There are several limitations to this study. The data used were obtained from the BENDITA trial13,49, which was not designed for the aim of
our ‘retrospective’ analysis (the low number of patients per treatment group preventing comparison of efficacy between treatment regimens). Moreover, the possible spontaneous cure of some
placebo-treated patients over time makes them indistinguishable from patients that show the decline due to medication. These factors could probably explain the low power to detect possible
differences between antibodies for treatment and placebo groups. However, even with the small sample size available, we were able to show significantly faster decline in antibodies in the
treatment groups compared to the placebo group, with the MultiCruzi test combined with the serial dilution technique. Due to the absence of validated biomarkers and/or tests, and to the
fluctuating levels of parasitemia, some seropositive patients were excluded from the study because of negative PCR results. Moreover, all patients were from Bolivia, where DTU V _T cruzi_ is
the dominant parasite strain; additional studies on patients with _T. cruzi_ from other DTUs are needed. The prediction model will need to be assessed and adjusted for additional study
cohorts, such as adults from other regions, because the duration and timing of the infection affect the serological course post-treatment. While the antigens in MultiCruzi were selected for
their high diagnostic performances and ability to cover various DTUs33, further testing in patients from different regions who are followed over time will help assess how antibody levels
evolve across Latin America and identify the specific antigens out of the 15 present in the test that contribute to evaluating treatment response. Adult’s antibody dynamics are known to be
slow, taking decades and since patients were only followed-up for 1 year, correlation with full seroreversion cannot be determined, as the necessary data will only be available after an
extended period (decades) due to slow seroreversion after cure of Chagas disease spontaneously or following treatment. In conclusion, we propose a method that shows the antibody signatures
and their dynamic decline in reactivity for each treated patient already 6 months after treatment with benznidazole, anticipating the future seroreversion. We highly recommend integrating
this new methodology as an endpoint into future Chagas disease clinical trials. METHODS CLINICAL TRIAL SAMPLES Serum samples drawn during the BENDITA (BEnznidazole New Doses Improved
Treatment and Associations) phase II double-blind randomized trial13,49 were stored at −80 °C following written consent of patients for further use for research purposes. Serum samples
corresponding to the timepoints at baseline (screening for inclusion before treatment start), 6 months, and 12 months after treatment were sent to InfYnity Biomarkers for evaluation with the
MultiCruzi assay31,32. The results obtained with the conventional serological tests were compared with those obtained with MultiCruzi at the tested timepoints. SEROLOGY CONVENTIONAL AND
RECOMBINANT ELISA SEROLOGY ASSAYS Serology was assessed to detect peripheral anti-_T. cruzi_ antibodies using two serological tests: the conventional ELISA kit (CHAGATEK ELISA, Laboratorio
Lemos SRL, Argentina) containing purified _T. cruzi_ antigens in serum and plasma and a recombinant ELISA kit I (Chagatest ELISA recombinante, V3.0, Wiener Lab, Argentina) made of six very
conserved recombinant antigens (1, 2, 13, 30, 36 and SAPA). Both tests were conducted on samples collected at baseline and 12 months after treatment following the manufacturers’
instructions13. Samples were stored at −80 °C with the written consent of patients and the serum samples drawn at screening, 6 months and 12 months after treatment were then evaluated with
MultiCruzi to monitor serological signatures and evaluate its usefulness as a predictive tool for parasitological cure as previously described in mice and in children31,32,50. MULTIPLEX
IMMUNOASSAY: MULTICRUZI The MultiCruzi immunoassay is a multiplex ELISA test incorporating 15 different _T. cruzi_ antigens31,32,33. The latter were printed (arrayed) in duplicate in each
well of 96-well microtiter plates (Supplementary Fig. 8). The printed antigens were identified from 15 protein immunodominant regions of _T. cruzi_ and were designed and synthesized
according to reviewed and published nonredundant sequences from UniProt (Supplementary Table 11). Among the printed 15 antigens, three are derived from discrete typing unit (DTU) specific
antigens from TcI, TcII, and TcVI protein regions of the _T cruzi_ DTU. The twelve remaining antigen sequences are highly conserved across _T. cruzi_ strains and DTUs. In addition, positive
control spots are printed in quadruplicate to verify that all test reagents are functional and are sequentially added in the correct order: serum samples, enzymatic-conjugate, and then
substrate. These control spots also define a spatial orientation of the array for the reader’s camera. Moreover, cutoff control and medium control spots were added in duplicate. The
MultiCruzi assay was carried out as previously described33 at three different sample dilutions (see “Serial dilutions” below). In summary, microplates were incubated with sera from patients,
diluted at 1:50, 1:400, and 1:3200, for 1 h at room temperature, then washed three times with phosphate-buffered saline with Tween buffer (PBST). Horseradish Peroxidase-conjugated goat
anti-human IgG antibodies (SouthernBiotech, Ref 2040-05) diluted at 1:2000 were added, incubated for another hour, and washed three times. TMB solution (SDT GmbH, Baesweiler, Germany) was
then added and incubated in the dark for 20 min at room temperature. Finally, the TMB solution was removed, and the plates were dried at 37 °C for 10 min. This test detects specific IgG
antibodies against 15 _T. cruzi_ antigens, specific differing informative antibody profiles for each sample. Every well on the plate was imaged, and the spot signals were analyzed using a
colorimetric reader. Mean spot intensities were normalized by dividing the obtained value for each antigen by the average positive control intensity, thus obtaining the maximum attainable
intensity in the assay defined as 100%. This method aimed at reducing assay variability and allowing the fixation of a common pixel intensity range of [0–100] for all tested antigens. The
data were incorporated into a statistical analysis package and analyzed accordingly. Each batch of printed MultiCruzi plates was validated after testing six _T. cruzi_ positive sera or
plasma samples with different levels of reactivity to the 15 antigens and two negative samples coming from healthy blood donors. For the determination of intra-assay precision, Coefficients
of variation (standard deviation/mean x 100), CV% were calculated for each antigen by testing in triplicates 8 _Trypanosoma cruzi_ positive human serum sample with different levels of
reactivities (Supplementary Table 12). DATABASE The raw data obtained from the image analysis reader were validated using the internal controls embedded in each test. The mean pixel
intensity of the reaction was corrected for background noise, expressed as a value ranging between 0 and 130, and used without preprocessing in the analysis. Inconsistent or aberrant signal
measures or antigen patterns were retested. Patients who withdrew from the study or who discontinued early were eliminated from the analysis. Validated data were incorporated into a
Microsoft Excel 2016 database for further analysis. SERIAL DILUTIONS When plotting the colorimetric intensity of each biomarker against the dilution factor, the resultant curve has a
sigmoidal shape with one plateau at high signal to no signal after multiple dilutions of the same sample (Supplementary Note 1, Supplementary Fig. 1a, b). We hypothesized that after
successful treatment, the sigmoidal curve shifts to lower dilution factors, and since this ‘shift’ can be measured, the treatment effect can be quantified. Quantification is better assessed
within the linear range of the curve. At extreme signal values (low and high), a minor change in signal intensity does not lead to an accurate estimation of the change in antibody levels—at
the usual dilution factor for routine diagnostic testing with MultiCruzi (1/50), signals are high and remain high a year after infection, while the sigmoidal curve shifts from day 0. To
ensure reading each antigen within the linear range, samples were serially diluted as has previously been described34. The dilution factors were defined such that overlap of linear ranges
for all antigens was assured, maximal concentrations could be quantified, and the number of dilutions was minimized (to reduce operational costs). See more details in Supplementary Note 1.
Finally, we selected 3 dilutions (1/50, 1/400 and 1/3200) that were best suited for all 15 antigens. Information on the shift of the sigmoidal curve is given by the DF50 value, the estimated
dilution factor corresponding to a signal of 50% (between top and bottom). The DF50 value was obtained for each serial dilution. For each patient, in each treatment group, three timepoints
(baseline, 6 months and 12 months) were used to calculate three DF50-values. The sigmoidal curve was expected to shift to lower dilution factors after effective treatment, meaning that
DF50-values shift to lower values. The log2(DF50) was, therefore, considered the dependent variable of interest. LINEAR MIXED MODELLING A random intercept linear mixed model (LMM) was
applied to explain the variability in log2(DF50) with time, treatment, and the interaction between time and treatment as explaining variables. The intercept and slope were obtained, and the
slopes were compared between the treatment and placebo groups. This approach was applied to (i) each antigen separately, which allows for the evaluation of the response to treatment for each
MultiCruzi antigen separately and (ii) using a nested LMM, keeping the connection between the patient and the antigens. This allows the evaluation of the response to treatment for all 15
MultiCruzi antigens together. Some antigens were not reactive at baseline, or the reactivity was very low, resulting in DF50-values which were very low (much lower than the initial dilution
factor). DF50-values that were estimated as very low, were set to 0.1. On the other side of the dilution factor range, it was possible that DF50-values would be extrapolated beyond the
highest dilution factor of 3200. We allowed one dilution factor outside the range 50–3200, but when DF50 was estimated >6400, the DF50-value was set to 6400. The effect of the presence of
DF50-values of 0.1 was evaluated by performing the analysis with and without the presence of such DF50-values. The LMM analysis was performed at three time-points (baseline, 6 months, and
12 months) but also on the more restricted timescale of 6 months (baseline + 6 months) to evaluate the possibility of using the analysis to reveal treatment response within the first 6
months after treatment start. See “Supplementary Information” for the detailed mathematical and statistical procedures. REPORTING SUMMARY Further information on research design is available
in the Nature Portfolio Reporting Summary linked to this article. DATA AVAILABILITY All data generated in this study are provided in the “Supplementary Software 1” zip file. The data
underlying the results presented in this study are available upon request because they contain potentially sensitive personal information, which must be deidentified at the individual level.
Interested researchers may contact the Drugs for Neglected Diseases initiative (DNDi), commissioner of this study, for data access requests via email at [email protected]. Researchers may
also request data by completing the form available at https://www.dndi.org/category/clinical-trials/. In this, they confirm that they will share data and results with DNDi and will publish
any results open access. CODE AVAILABILITY A Visual Basic for Applications (VBA 7.1) User Defined Function from Microsoft Excel 2016 was programmed to calculate the DF50-value from the DFs
and biomarker intensities (Y-values). Linear Mixed Model analysis was performed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA). The code is available in the “Supplementary Software 1”
file. REFERENCES * Pérez-Molina, J. A. & Molina, I. Chagas disease. _Lancet_ 391, 82–94 (2018). Article PubMed Google Scholar * WHO. _Chagas Disease._
https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis) (2023). * Rassi, A., Rassi, A. & Marcondes de Rezende, J. American trypanosomiasis (Chagas
Disease). _Infectious Disease Clinics of North America_ 26, 275–291 (2012). Article PubMed Google Scholar * Edwards, M. S. & Montgomery, S. P. Congenital Chagas disease: progress
toward implementation of pregnancy-based screening. _Curr Opin Infect Dis_ 34, 538–545 (2021). Article PubMed PubMed Central Google Scholar * Nunes, M. C. P. et al. Chagas
cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American heart association. _Circulation_ 138, e169–e209 (2018). Article PubMed
Google Scholar * Echeverria, L. E. & Morillo, C. A. American trypanosomiasis (Chagas Disease). _Infect. Dis. Clin. N. Am._ 33, 119–134 (2019). Article Google Scholar * Ribeiro, A. L.
P., Marcolino, M. S., Prineas, R. J. & Lima-Costa, M. F. Electrocardiographic abnormalities in elderly Chagas disease patients: 10 year follow-up of the bambui cohort study of aging. _J
Am. Heart Assoc._ 3, e000632 (2014). Article PubMed PubMed Central Google Scholar * Pan American Health Organization. _Guidelines for the Diagnosis and Treatment of Chagas Disease._
https://iris.paho.org/handle/10665.2/49653 (2019). * Jackson, Y., Wyssa, B. & Chappuis, F. Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease. _J.
Antimicrob. Chemother._ 75, 690–696 (2020). Article CAS PubMed Google Scholar * Altcheh, J., Moscatelli, G., Moroni, S., Garcia-Bournissen, F. & Freilij, H. Adverse events after the
use of benznidazole in infants and children with Chagas disease. _Pediatrics_ 127, e212–e218 (2011). Article PubMed Google Scholar * Sguassero, Y. et al. Course of chronic trypanosoma
cruzi infection after treatment based on parasitological and serological tests: a systematic review of follow-up studies. _PLoS One_ 10, e0139363 (2015). Article PubMed PubMed Central
Google Scholar * Hasslocher-Moreno, A. M. et al. Safety of benznidazole use in the treatment of chronic Chagas’ disease. _J. Antimicrob. Chemother._ 67, 1261–1266 (2012). Article CAS
PubMed Google Scholar * Torrico, F. et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2,
double-blind, randomised trial. _Lancet Infect. Dis._ 21, 1129–1140 (2021). Article CAS PubMed Google Scholar * Bustamante, J. M., Craft, J. M., Crowe, B. D., Ketchie, S. A. &
Tarleton, R. L. New, combined, and reduced dosing treatment protocols cure trypanosoma cruzi infection in mice. _J. Infect. Dis._ 209, 150–162 (2014). Article CAS PubMed Google Scholar *
Chatelain, E. & Konar, N. Translational challenges of animal models in Chagas disease drug development: a review. _DDDT_ 9, 4807–4823 (2015). Article CAS PubMed PubMed Central
Google Scholar * Bustamante, J. M. & Tarleton, R. L. Methodological advances in drug discovery for Chagas disease. _Expert Opin. Drug Discov._ 6, 653–661 (2011). Article CAS PubMed
PubMed Central Google Scholar * Kratz, J. M. Drug discovery for chagas disease: a viewpoint. _Acta. Tropica._ 198, 105107 (2019). Article CAS PubMed Google Scholar * Schijman, A. G. et
al. International study to evaluate PCR methods for detection of trypanosoma cruzi DNA in blood samples from Chagas disease patients. _PLoS Negl. Tropica. Dis._ 5, e931 (2011). Article CAS
Google Scholar * Fernandes, M. C. & Andrews, N. W. Host cell invasion by trypanosoma cruzi: a unique strategy that promotes persistence. _FEMS Microbiol Rev_ 36, 734–747 (2012).
Article CAS PubMed Google Scholar * Grossmann, U. & Rodriguez, M.-L. Chagas disease treatment efficacy markers: experiences from a phase III study with nifurtimox in children.
_Front. Parasitol._ https://doi.org/10.3389/fpara.2023.1229467 (2023). * _Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood
Components._ https://www.fda.gov/regulatory-information (2017). * Alonso-Padilla, J. et al. Target product profile for a test for the early assessment of treatment efficacy in Chagas disease
patients: an expert consensus. _PLOS Neglected Trop. Dis._ 14, e0008035 (2020). Article Google Scholar * Viotti, R. et al. Impact of aetiological treatment on conventional and multiplex
serology in Chronic Chagas disease. _PLoS Negl. Trop. Dis._ 5, e1314 (2011). Article PubMed PubMed Central Google Scholar * Viotti, R. et al. Towards a paradigm shift in the treatment of
chronic Chagas disease. _Antimicrob. Agents Chemother._ 58, 635–639 (2014). Article CAS PubMed PubMed Central Google Scholar * Traynor, K. Benznidazole approved for Chagas disease in
children. _Am. J. Health Syst. Pharmacy_ 74, 1519 (2017). Article Google Scholar * Altcheh, J. et al. Prospective, historically controlled study to evaluate the efficacy and safety of a
new paediatric formulation of nifurtimox in children aged 0 – 17 years with Chagas disease one year after treatment (CHICO). _PLoS Negl. Trop. Dis._ 15, e0008912 (2021). Article CAS PubMed
PubMed Central Google Scholar * Balouz, V., Agüero, F. & Buscaglia, C. A. Chagas disease diagnostic applications: present knowledge and future steps. _Adv Parasitol_ 97, 1–45 (2017).
Article CAS PubMed Google Scholar * Buss, L. F. et al. Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic
changes in a retrospective cohort of untreated Brazilian blood donors. _PLoS Neglected Trop. Dis._ 14, e0008787 (2020). Article CAS Google Scholar * Afonso, A. M., Ebell, M. H. &
Tarleton, R. L. A systematic review of high quality diagnostic tests for Chagas disease. _PLoS Negl Trop Dis_ 6, e1881 (2012). Article PubMed PubMed Central Google Scholar * Ricci, A. D.
et al. The trypanosoma cruzi antigen and epitope atlas: antibody specificities in Chagas disease patients across the Americas. _Nat. Commun._ 14, 1850 (2023). Article CAS PubMed PubMed
Central Google Scholar * Medina, L. J. et al. Prediction of parasitological cure in children infected with trypanosoma cruzi using a novel multiplex serological approach: an observational,
retrospective cohort study. _Lancet Infect. Dis._ 21, 1141–1150 (2021). Article Google Scholar * Zrein, M. et al. A novel antibody surrogate biomarker to monitor parasite persistence in
Trypanosoma cruzi-infected patients. _PLoS Neglected Trop. Dis._ 12, e0006226 (2018). Article Google Scholar * Granjon, E. et al. Development of a novel multiplex immunoassay multi-cruzi
for the serological confirmation of Chagas disease. _PLoS Neglected Trop. Dis._ 10, e0004596 (2016). Article Google Scholar * Boer et al. A novel assessment method for COVID-19 humoral
immunity duration using serial measurements in naturally infected and vaccinated subjects. _PLoS One_ 17, e0274553 (2022). Article PubMed PubMed Central Google Scholar * Dias, J. C. P.
et al. Further evidence of spontaneous cure in human Chagas disease. _Rev. Soc. Bras. Med. Trop._ 41, 505–506 (2008). Article PubMed Google Scholar * Francolino, S. S. et al. New evidence
of spontaneous cure in human Chagas’ disease. _Rev. Soc. Bras. Med. Trop._ 36, 103–107 (2003). Article PubMed Google Scholar * Remesar, M. et al. Bimodal distribution of Trypanosoma
cruzi antibody levels in blood donors from a highly endemic area of Argentina: what is the significance of low-reactive samples? _Transfusion_ 55, 2499–2504 (2015). Article CAS PubMed
Google Scholar * Watson, J. A. et al. Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of
concept trials. _medRxiv_ https://doi.org/10.1101/2024.07.14.24310398 (2024). * Alonso-Padilla, J., Gallego, M., Schijman, A. G. & Gascon, J. Molecular diagnostics for Chagas disease: up
to date and novel methodologies. _Expert Rev. Mol. Diagn._ 17, 699–710 (2017). Article CAS PubMed Google Scholar * Molina-Morant, D. et al. Efficacy and safety assessment of different
dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized phase II superiority clinical trial.
_Trials_ 21, 328 (2020). Article CAS PubMed PubMed Central Google Scholar * Molina, I. et al. Randomized trial of posaconazole and benznidazole for Chronic Chagas’ disease. _N. Engl. J.
Med._ 370, 1899–1908 (2014). Article PubMed Google Scholar * Sulleiro, E. et al. Usefulness of real-time PCR during follow-up of patients treated with Benznidazole for chronic Chagas
disease: Experience in two referral centers in Barcelona. _PLoS Negl. Trop. Dis._ 14, e0008067 (2020). Article PubMed PubMed Central Google Scholar * Duffy, T. et al. Analytical
performance of a multiplex real-time PCR assay using TaqMan probes for quantification of trypanosoma cruzi satellite DNA in blood samples. _PLoS Negl. Trop. Dis._ 7, e2000 (2013). Article
CAS PubMed PubMed Central Google Scholar * Saldaña, A. et al. Predominance of Trypanosoma rangeli infection in children from a Chagas disease endemic area in the west-shore of the Panama
canal. _Mem. Inst. Oswaldo Cruz._ 100, 729–731 (2005). Article PubMed Google Scholar * Ramirez, L. E. et al. High prevalence of trypanosoma rangeli and Trypanosoma cruzi in opossums and
triatomids in a formerly-endemic area of Chagas disease in Southeast Brazil. _Acta. Trop._ 84, 189–198 (2002). Article PubMed Google Scholar * Saldaña, A. & Sousa, O. E. Trypanosoma
rangeli: epimastigote immunogenicity and cross-reaction with Trypanosoma cruzi. _J. Parasitol._ 82, 363–366 (1996). Article PubMed Google Scholar * Zrein, M. & Chatelain, E. The unmet
medical need for Trypanosoma cruzi-infected patients: monitoring the disease status. _Biochim. Biophys. Acta Mol. Basis Dis._ 1866, 165628 (2020). Article CAS PubMed Google Scholar *
PLOS Neglected Tropical Diseases. _Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources?_
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005148 (2017). * Drugs for Neglected Diseases. _Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate
Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease._
https://clinicaltrials.gov/study/NCT03378661 (2017). * Francisco, A. F. et al. Comparing in vivo bioluminescence imaging and the multi-cruzi immunoassay platform to develop improved Chagas
disease diagnostic procedures and biomarkers for monitoring parasitological cure. _PLoS Negl. Trop. Dis._ 16, e0010827 (2022). Article CAS PubMed PubMed Central Google Scholar Download
references ACKNOWLEDGEMENTS I.S. and E.C. wish to thank colleagues at DNDi for their valuable support and scientific input during this project. This work was partially funded by DNDi. For
these activities, DNDi received funding from UK Aid, UK; and for its overall mission, from Médecins Sans Frontières International. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * InfYnity
Biomarkers, Lyon, France Ursula Saade & Maan Zrein * Swiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, 4123, Allschwil, Switzerland
Ursula Saade * University of Basel, 4001, Basel, Switzerland Ursula Saade * Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium Jasper de Boer
& Hans Pottel * Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland Ivan Scandale & Eric Chatelain * Parasitology Service, Hospital de Niños “Ricardo Gutierrez” and
Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP)-CONICET-GCBA, Buenos Aires, Argentina Jaime Altcheh Authors * Ursula Saade View author publications You can
also search for this author inPubMed Google Scholar * Jasper de Boer View author publications You can also search for this author inPubMed Google Scholar * Ivan Scandale View author
publications You can also search for this author inPubMed Google Scholar * Jaime Altcheh View author publications You can also search for this author inPubMed Google Scholar * Hans Pottel
View author publications You can also search for this author inPubMed Google Scholar * Eric Chatelain View author publications You can also search for this author inPubMed Google Scholar *
Maan Zrein View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS U.S., I.S., E.C., and M.Z. conceived the idea for the project. U.S., M.Z., H.P.,
and J.dB. developed or designed the methodology and assays / models used in these studies. U.S. performed the assays, measurements and data visualization. M.Z., E.C. and I.S. were
responsible for the administration of the project. M.Z., E.C. and I.S. supervised the studies. M.Z., E.C. and I.S. were involved in funding acquisition. U.S., M.Z. and H.P. wrote the
original draft. U.S., M.Z., H.P., J.dB., E.C., I.S. and J.A. reviewed and edited the original draft. J.A. contributed to the administrative and logistics aspects of the study. All authors
read, revised and authorized the manuscript before submission. CORRESPONDING AUTHORS Correspondence to Eric Chatelain or Maan Zrein. ETHICS DECLARATIONS COMPETING INTERESTS U.S. and M.Z. are
employed by InfYnity Biomarkers. All other authors declare no competing interests. PEER REVIEW PEER REVIEW INFORMATION _Nature Communications_ thanks James Watson, who co-reviewed with
Cintia Cruz and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer
Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION PEER REVIEW FILE DESCRIPTION
OF ADDITIONAL SUPPLEMENTARY FILES SUPPLEMENTARY SOFTWARE 1 REPORTING SUMMARY RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission
under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by-nc-nd/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Saade, U., de Boer, J., Scandale, I. _et al._ Early assessment of antibodies
decline in Chagas patients following treatment using a serological multiplex immunoassay. _Nat Commun_ 15, 10530 (2024). https://doi.org/10.1038/s41467-024-54910-x Download citation *
Received: 27 February 2024 * Accepted: 25 November 2024 * Published: 03 December 2024 * DOI: https://doi.org/10.1038/s41467-024-54910-x SHARE THIS ARTICLE Anyone you share the following link
with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt
content-sharing initiative